In an abrupt and shocking twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his place as the top of the corporate. The Dutch pharmaceutical big introduced Friday that, amidst a current downturn within the firm’s inventory, Lars Fruergaard Jørgensen would quickly be stepping down as its prime govt and the board would search a successor for him.
“As per mutual settlement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his function as CEO of Novo Nordisk,” the corporate mentioned, in a press launch. “He’ll proceed as CEO for a interval to assist a clean transition to new management.”
It absolutely appears odd that Novo Nordisk isn’t doing too properly. In any case, it’s the corporate behind a breakthrough drug, semaglutide, that may make seemingly anybody—from Jim Gaffigan to Oprah—shed kilos immediately. Nonetheless, whereas Ozempic and Wegovy have secured standing as international family names, Novo Nordisk’s inventory value has seen a vital downturn over the previous yr, as competitor manufacturers have crept into the market. In its assertion on Jorgensen’s ousting, the pharmaceutical firm notes that the swiftly altering panorama for weight reduction merchandise is what has led to the shakeup in firm management. “The modifications are made in mild of the current market challenges Novo Nordisk has been dealing with, and the event of the corporate’s share value since mid-2024,” the press launch from the corporate reads.
It additionally notes, nonetheless, that Jorgensen managed to shepherd the corporate into steadily higher financial waters for the higher a part of a decade earlier than market troubles hit in 2024: “Throughout his eight-year tenure as CEO, Novo Nordisk’s gross sales, income and share value have nearly tripled,” the corporate writes. “Contemplating the current market challenges, the share value decline, and the want from the Novo Nordisk Basis, the Novo Nordisk Board and Lars Fruergaard Jørgensen have collectively concluded that initiating a CEO succession is in the perfect curiosity of the corporate and its shareholders.”
Gizmodo reached out to Novo Nordisk for extra data and can replace this story if it responds.
